The results of a Phase 3 trial investigating tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma were published on January 1, 2024. This study, known as the TiN trial, evaluated the combination therapy in patients who had previously received an immune checkpoint inhibitor.
Background
The published study focused on renal cell carcinoma, specifically in patients who had previously undergone treatment with an immune checkpoint inhibitor. The trial compared a combination of tivozanib and nivolumab against tivozanib monotherapy in this patient population.
Trial design
The Phase 3 TiN trial was designed to compare the efficacy and safety of tivozanib in combination with nivolumab against tivozanib monotherapy. The study population consisted of patients diagnosed with renal cell carcinoma who had previously received an immune checkpoint inhibitor.
What this means
The publication of the Phase 3 TiN trial results provides clinicians and researchers with data on the comparative efficacy and safety of tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma who have previously received an immune checkpoint inhibitor. While specific outcomes are not detailed in the provided information, the availability of these results allows for a comprehensive review of the trial's findings regarding this treatment approach.
Source
The information regarding these trial results was obtained from a publication on PubMed, dated January 1, 2024. The article, titled "Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiN (Lancet)", is accessible via pubmed.ncbi.nlm.nih.gov.